209 related articles for article (PubMed ID: 21482774)
1. Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen.
Mendes-Pereira AM; Sims D; Dexter T; Fenwick K; Assiotis I; Kozarewa I; Mitsopoulos C; Hakas J; Zvelebil M; Lord CJ; Ashworth A
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2730-5. PubMed ID: 21482774
[TBL] [Abstract][Full Text] [Related]
2. A genome-wide RNAi screen identifies novel targets of neratinib resistance leading to identification of potential drug resistant genetic markers.
Seyhan AA; Varadarajan U; Choe S; Liu W; Ryan TE
Mol Biosyst; 2012 Apr; 8(5):1553-70. PubMed ID: 22446932
[TBL] [Abstract][Full Text] [Related]
3. A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.
Thrane S; Pedersen AM; Thomsen MB; Kirkegaard T; Rasmussen BB; Duun-Henriksen AK; Lænkholm AV; Bak M; Lykkesfeldt AE; Yde CW
Oncogene; 2015 Aug; 34(32):4199-210. PubMed ID: 25362855
[TBL] [Abstract][Full Text] [Related]
4. miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22.
Li J; Lu M; Jin J; Lu X; Xu T; Jin S
Cell Physiol Biochem; 2018; 50(1):136-149. PubMed ID: 30278449
[TBL] [Abstract][Full Text] [Related]
5. ERα-XPO1 Cross Talk Controls Tamoxifen Sensitivity in Tumors by Altering ERK5 Cellular Localization.
Wrobel K; Zhao YC; Kulkoyluoglu E; Chen KL; Hieronymi K; Holloway J; Li S; Ray T; Ray PS; Landesman Y; Lipka AE; Smith RL; Madak-Erdogan Z
Mol Endocrinol; 2016 Oct; 30(10):1029-1045. PubMed ID: 27533791
[TBL] [Abstract][Full Text] [Related]
6. VAV3 mediates resistance to breast cancer endocrine therapy.
Aguilar H; Urruticoechea A; Halonen P; Kiyotani K; Mushiroda T; Barril X; Serra-Musach J; Islam A; Caizzi L; Di Croce L; Nevedomskaya E; Zwart W; Bostner J; Karlsson E; Pérez Tenorio G; Fornander T; Sgroi DC; Garcia-Mata R; Jansen MP; García N; Bonifaci N; Climent F; Soler MT; Rodríguez-Vida A; Gil M; Brunet J; Martrat G; Gómez-Baldó L; Extremera AI; Figueras A; Balart J; Clarke R; Burnstein KL; Carlson KE; Katzenellenbogen JA; Vizoso M; Esteller M; Villanueva A; Rodríguez-Peña AB; Bustelo XR; Nakamura Y; Zembutsu H; Stål O; Beijersbergen RL; Pujana MA
Breast Cancer Res; 2014 May; 16(3):R53. PubMed ID: 24886537
[TBL] [Abstract][Full Text] [Related]
7. Protein phosphatase 1, regulatory subunit 15B is a survival factor for ERα-positive breast cancer.
Shahmoradgoli M; Riazalhosseini Y; Haag D; Becker N; Hovestadt V; Heck S; Sinn HP; Schneeweiss A; Mannherz O; Sahin Ö; Lichter P
Int J Cancer; 2013 Jun; 132(11):2714-9. PubMed ID: 23169272
[TBL] [Abstract][Full Text] [Related]
8. Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells.
Godinho M; Meijer D; Setyono-Han B; Dorssers LC; van Agthoven T
J Cell Physiol; 2011 Jul; 226(7):1741-9. PubMed ID: 21506106
[TBL] [Abstract][Full Text] [Related]
9. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.
Ramaswamy B; Lu Y; Teng KY; Nuovo G; Li X; Shapiro CL; Majumder S
Cancer Res; 2012 Oct; 72(19):5048-59. PubMed ID: 22875023
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer.
Ward A; Shukla K; Balwierz A; Soons Z; König R; Sahin O; Wiemann S
J Pathol; 2014 Aug; 233(4):368-79. PubMed ID: 24752803
[TBL] [Abstract][Full Text] [Related]
11. Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response.
van Agthoven T; Sieuwerts AM; Meijer D; Meijer-van Gelder ME; van Agthoven TL; Sarwari R; Sleijfer S; Foekens JA; Dorssers LC
Endocr Relat Cancer; 2010 Mar; 17(1):215-30. PubMed ID: 19966015
[TBL] [Abstract][Full Text] [Related]
12. Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells.
Meijer D; van Agthoven T; Bosma PT; Nooter K; Dorssers LC
Mol Cancer Res; 2006 Jun; 4(6):379-86. PubMed ID: 16778085
[TBL] [Abstract][Full Text] [Related]
13. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
14. Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer.
Shah KN; Wilson EA; Malla R; Elford HL; Faridi JS
Mol Cancer Ther; 2015 Nov; 14(11):2411-21. PubMed ID: 26333382
[TBL] [Abstract][Full Text] [Related]
15. LncRNA LINP1 confers tamoxifen resistance and negatively regulated by ER signaling in breast cancer.
Ma T; Liang Y; Li Y; Song X; Zhang N; Li X; Chen B; Zhao W; Wang L; Yang Q
Cell Signal; 2020 Apr; 68():109536. PubMed ID: 31927036
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity.
Lindberg K; Helguero LA; Omoto Y; Gustafsson JÅ; Haldosén LA
Breast Cancer Res; 2011 Apr; 13(2):R43. PubMed ID: 21492444
[TBL] [Abstract][Full Text] [Related]
17. Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties.
Lin X; Li J; Yin G; Zhao Q; Elias D; Lykkesfeldt AE; Stenvang J; Brünner N; Wang J; Yang H; Bolund L; Ditzel HJ
Breast Cancer Res; 2013 Dec; 15(6):R119. PubMed ID: 24355041
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of BAG‑1 in T47D cells promotes resistance to tamoxifen via activation of the PI3K/Akt/mTOR signaling pathway.
Lu S; Du Y; Cui F; Feng X; Ma Y; Liu H
Oncol Rep; 2019 Mar; 41(3):1901-1910. PubMed ID: 30747221
[TBL] [Abstract][Full Text] [Related]
19. A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance.
Miller TW; Balko JM; Ghazoui Z; Dunbier A; Anderson H; Dowsett M; González-Angulo AM; Mills GB; Miller WR; Wu H; Shyr Y; Arteaga CL
Clin Cancer Res; 2011 Apr; 17(7):2024-34. PubMed ID: 21346144
[TBL] [Abstract][Full Text] [Related]
20. IL-33 facilitates endocrine resistance of breast cancer by inducing cancer stem cell properties.
Hu H; Sun J; Wang C; Bu X; Liu X; Mao Y; Wang H
Biochem Biophys Res Commun; 2017 Apr; 485(3):643-650. PubMed ID: 28216163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
